Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2002-6-28
pubmed:abstractText
To test the hypothesis that a chemotherapy regimen of relatively low toxicity and 11 weeks' duration (doxorubicin, cyclophosphamide, etoposide, vincristine, bleomycin, and prednisolone [VAPEC-B]) is at least as effective in terms of disease control as 6 months' treatment with chlorambucil, vinblastine, procarbazine, and prednisone/etoposide, vincristine, and doxorubicin (ChlVPP/EVA hybrid), which is associated with a high risk of permanent sterility.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2988-94
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:12089229-Adolescent, pubmed-meshheading:12089229-Adult, pubmed-meshheading:12089229-Aged, pubmed-meshheading:12089229-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12089229-Bleomycin, pubmed-meshheading:12089229-Chlorambucil, pubmed-meshheading:12089229-Cyclophosphamide, pubmed-meshheading:12089229-Doxorubicin, pubmed-meshheading:12089229-Etoposide, pubmed-meshheading:12089229-Female, pubmed-meshheading:12089229-Great Britain, pubmed-meshheading:12089229-Hodgkin Disease, pubmed-meshheading:12089229-Humans, pubmed-meshheading:12089229-Incidence, pubmed-meshheading:12089229-Italy, pubmed-meshheading:12089229-Male, pubmed-meshheading:12089229-Middle Aged, pubmed-meshheading:12089229-Neoplasm Staging, pubmed-meshheading:12089229-Neoplasms, Second Primary, pubmed-meshheading:12089229-Prednisolone, pubmed-meshheading:12089229-Procarbazine, pubmed-meshheading:12089229-Prognosis, pubmed-meshheading:12089229-Treatment Outcome, pubmed-meshheading:12089229-Vinblastine, pubmed-meshheading:12089229-Vincristine
pubmed:year
2002
pubmed:articleTitle
ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.
pubmed:affiliation
Department of Medical Oncology, Christie Hospital, Manchester, UK. john.radford@man.ac.uk
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Multicenter Study